“Dr. Julio S. G. Montaner of Vancouver found that inclusion of a drug known as nevirapine
instead of a protease inhibitor showed similar benefit.”
“Dr. Julio S. G. Montaner of Vancouver found that inclusion of a drug known as nevirapine
instead of a protease inhibitor showed similar benefit.”
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below